EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$105.20M
• Dividend Yield: 1.6%
• Average Volume (3M): 49.70K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.53
• Revenue Growth: 0.65%
• EPS Growth: -9.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 47,173,200
• 10 Day Avg. Volume: 67,551
• 30 Day Avg. Volume: 49,696
• PEG Ratio: -2.57
• Price to Book (P/B): 3.85
• Price to Sales (P/S): 1.62
• P/FCF Ratio: 26.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: AU$2.50 ▲(3.31% Upside)

EZZ Life Science Holdings Ltd. has a solid financial foundation with strong profitability and a robust balance sheet. However, technical indicators suggest short-term bearish momentum, and valuation metrics do not indicate significant undervaluation. The absence of recent earnings call data and corporate events limits further insights.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Ltd. (EZZ) is a health and wellness company focused on developing, manufacturing, and distributing innovative dietary supplements and health products. Operating primarily in the nutraceutical sector, EZZ offers a range of products aimed at enhancing health and well-being, including supplements that support immune health, energy levels, and overall vitality. The company emphasizes research and development to create high-quality formulations that cater to the evolving needs of health-conscious consumers.

How the Company Makes Money

EZZ generates revenue through the sale of its dietary supplements and health products, which are marketed both online and through retail partnerships. The company employs a multi-channel distribution strategy, leveraging e-commerce platforms and traditional retail outlets to reach a broad audience. Key revenue streams include direct-to-consumer sales via their website and partnerships with health and wellness retailers. Additionally, EZZ may engage in strategic collaborations with other companies in the health sector to expand its product offerings and market reach, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. exhibits strong financial health with significant revenue and profit growth. The income statement reflects an impressive 78.9% revenue increase, and the company maintains a high gross profit margin of 74.2%. The balance sheet is robust, supported by a low debt-to-equity ratio of 0.01 and a strong ROE of 32.7%. Cash flow metrics are solid, with a 46.6% increase in free cash flow, indicating efficient cash management.

Income Statement

EZZ Life Science Holdings Ltd. demonstrates strong revenue growth, with a 78.9% increase in total revenue from 2023 to 2024. The gross profit margin is robust at 74.2%, indicating efficient cost management. Net profit margin stands at 10.5%, showing healthy profitability, though there's room for improvement in converting revenue to net income. EBIT and EBITDA margins are solid at 14.6% and 15.6%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.01, showcasing a conservative leverage strategy. Return on Equity (ROE) is strong at 32.7%, indicating effective use of shareholders' equity. The equity ratio is high at 83.5%, highlighting financial stability and low financial risk. Overall, the balance sheet reflects a strong financial position with minimal debt.

Cash Flow

EZZ Life Science Holdings Ltd. shows a significant increase in free cash flow, with a growth rate of 46.6% from the previous year. The operating cash flow to net income ratio is 0.88, indicating efficient cash generation relative to reported earnings. The free cash flow to net income ratio is 0.82, suggesting that the company's operations are generating ample cash relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.87M	66.87M	66.44M	37.14M	15.02M	22.29M
Gross Profit	49.72M	49.72M	50.95M	27.20M	7.51M	12.46M
EBITDA	10.08M	11.10M	10.38M	5.09M	1.90M	2.87M
Net Income	6.73M	6.73M	6.96M	3.63M	1.31M	2.03M
Balance Sheet
Total Assets	33.96M	33.96M	25.55M	17.64M	14.27M	12.04M
Cash, Cash Equivalents and Short-Term Investments	20.85M	20.85M	19.02M	13.83M	10.46M	8.85M
Total Debt	304.49K	304.49K	123.86K	478.59K	104.57K	79.01K
Total Liabilities	5.87M	5.87M	4.23M	3.06M	2.88M	1.93M
Stockholders Equity	28.09M	28.09M	21.32M	14.58M	11.39M	10.11M
Cash Flow
Free Cash Flow	4.13M	4.09M	5.73M	3.91M	1.89M	237.42K
Operating Cash Flow	4.37M	4.35M	6.14M	4.01M	1.90M	253.53K
Investing Cash Flow	-546.93K	-546.93K	-441.17K	-101.78K	-13.18K	-16.12K
Financing Cash Flow	-2.17M	-2.17M	-582.45K	-761.72K	-277.36K	5.44M

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.42
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Neutral. The current price of 2.42 is below the 20-day moving average (MA) of 2.72, below the 50-day MA of 2.46, and above the 200-day MA of 2.03, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 33.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	64 Neutral	AU$105.20M	15.29	27.24%	1.60%	0.65%	-9.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCE	45 Neutral	AU$118.57M	-4.50	―	―	―	0.66%
ATX	42 Neutral	AU$61.57M	―	-41.60%	―	―	4.07%
ATH	41 Neutral	AU$108.75M	―	-42.68%	―	―	63.46%
IMU	41 Neutral	$100.90M	―	-83.09%	―	―	55.94%
ALA	40 Underperform	AU$106.68M	-13.09	-47.98%	―	700.00%	26.88%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Declares Final Dividend for 2025

EZZ Life Science Holdings Limited has announced a fully franked final dividend of $0.020 per share for the fiscal year ending 30 June 2025. The dividend will be paid on 23 December 2025, with an ex-dividend date of 24 November 2025 and a record date of 25 November 2025. This announcement reflects the company’s commitment to rewarding shareholders and may enhance its attractiveness to investors.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Expands Market Reach and Product Line Amidst Financial Challenges

EZZ Life Science Holdings Limited reported its quarterly activities and financials for Q1 FY26, highlighting strategic progress in market expansion and product innovation. The company made significant strides in the US market by shifting its marketing strategy towards performance-driven campaigns and expanding its retail channels, including discussions to enter the Walmart Marketplace. Domestically, EZZ expanded its pharmacy network and launched a new Shopify store to boost its retail presence in Australia. Despite a 25.4% drop in customer receipts due to deferred payments and seasonal factors in China, EZZ maintained a strong cash position of $17.3 million and remains debt-free. The company launched three new health products, reinforcing its competitive edge and commitment to innovation. Looking forward, EZZ aims to scale its brand in the US, drive growth in Southeast Asia, and continue expanding its Australian retail channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces 2025 AGM with Digital Access

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting (AGM) scheduled for November 28, 2025. The company will provide meeting materials electronically, following recent legislative changes, to enhance accessibility and environmental sustainability. Shareholders are encouraged to participate and submit their votes in advance through various online and offline channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces Annual General Meeting Agenda

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting to be held on November 28, 2025. Key agenda items include the consideration of financial statements, the adoption of the remuneration report, the re-election of director Glenn Cross, and the approval of a mandate to issue equity securities. These resolutions are significant as they impact the company’s governance and capital structure, potentially influencing shareholder value and strategic direction.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Sets AGM Date and Director Nomination Deadline

EZZ Life Science Holdings Limited has announced the date for its 2025 Annual General Meeting, which will be held on November 28, 2025. The company has also set October 17, 2025, as the closing date for director nominations. This announcement is part of EZZ’s ongoing efforts to strengthen its governance and strategic positioning in the genomic life sciences sector.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Reports Resilient Financial Performance Amidst Market Challenges

EZZ Life Science Holdings Ltd. reported a slight increase in revenue by 0.65% to $66.87 million for the year ending June 2025, while profits decreased by 3.36% to $6.73 million. Despite the decline in profit, the company saw an increase in net assets and share capital, indicating a strengthening financial position. The dividends remained consistent with the previous year, reflecting stable shareholder returns. These financial results suggest a resilient performance amidst challenging market conditions, potentially impacting stakeholder confidence positively.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.